Concepedia

Author

Patricia Rich

Cancer Treatment Centers of America

Also Known As

P. Rich, P. Thompson Rich, Patricia Rich, Patricia T. Rich

26

Publications

409

Citations

10

H-Index

22

Concepts

All Affiliations

Cancer Treatment Centers of AmericaSarah CannonHospital Regional Universitario de MálagaCase Western Reserve UniversitySoutheastern Health
PR

About

Patricia Rich is an author at Cancer Treatment Centers of America specializing in oncology, molecular oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

69

2

Immunology

2

2

29

3

Pathology

2

2

53

4

Cell Biology

1

1

16

5

Pharmacology

1

1

40

Patricia Rich

×

9

Publications

350

Citations

9

H-Index

YearCitations

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland,

Journal of Thoracic Oncology

2021

147

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Benjamin Tan, Adnan Khattak, Enriqueta Felip,

Targeted Oncology

2021

41

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Tareq Al Baghdadi, Elizabeth Garrett‐Mayer, Susan Halabi,

Targeted Oncology

2020

40

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R. Spigel, Afshin Dowlati, Yuanbin Chen,

Journal of Clinical Oncology

2024

29

Comparison of two PEG‐interferon alpha‐2b doses (1.0 or 1.5 <i>μ</i>g/kg) combined with ribavirin in interferon‐naïve patients with chronic hepatitis C and up to moderate fibrosis

B Meyer-Wyss, Patricia Rich, Hp Egger,

Journal of Viral Hepatitis

2006

26

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

Patricia Rich, R. Brian Mitchell, Eric Schaefer,

Journal for ImmunoTherapy of Cancer

2021

21

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Luis Paz‐Ares, David R. Spigel, Yuanbin Chen,

Cancer

2022

17

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.

Scott Kopetz, Alexander I. Spira, M. S. Wertheim,

Journal of Clinical Oncology

2018

16

Correlation between tumor mutation burden and response to immunotherapy.

Ioana Bonta, John Florin Isac, Eyal Meiri,

Journal of Clinical Oncology

2017

13

Page 1